Introduction: The incidence of multiple myeloma (MM) has increased in Scotland over the last 20 years. Approximately 25% of cases present directly to renal services. Serum electrophoresis is commonly included in the diagnostic screening tests performed in patients with chronic kidney disease (CKD). We examined the utility of serum electrophoresis in the population presenting to renal outpatient services in Glasgow. Methods: All new patient attendances at general nephrology clinics in the Glasgow renal units between 1/08/2004 and 31/07/2006, along with clinical data, were retrieved from the electronic patient records. Patients with acute kidney injury were excluded. All serum and urine electrophoresis requests and results for the same period were identified from Biochemistry and Immunology Laboratory Services. Results: A total of 2,544 new patients attended a renal clinic for the first time in the inception period, of whom 1,608 (63.2%) had serum electrophoresis tested. One patient with MM was identified, but the diagnosis was clinically apparent before the serum electrophoresis result was requested. A further 40 subjects had abnormal serum electrophoresis with mean paraprotein of 8.3 g/l (SD 6.1); none of these patients have subsequently developed MM, and the renal abnormalities are felt to be unrelated. This prevalence of monoclonal gammopathy of uncertain significance in 2.5% of the cohort is consistent with the expected prevalence in the general population. Conclusion: Our data demonstrate that serum electrophoresis in patients with CKD is not a useful screening test to identify MM.

Keywords:
Myeloma, Serum electrophoresis, Chronic kidney disease
1.
Chan DT, Craig K, Donovan K, Phillips A: Myeloma Renal Disease: Presentation and Outcome. Nephron Clin Pract 2006;104:c126–c131.
2.
Information Services Division, NHS National Services Scotland. http://www.isdscotland.org/isd/1543.html#Multiple%20myeloma (accessed June 2008).
3.
Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J; for the Nordic Myeloma Study Group: Renal function in newly diagnosed multiple myeloma – a demographic study of 1,353 patients. Eur J Haematol 1994;53:207–212.
4.
DeFronzo RA, Humphrey RL, Wright JR, Cooke CR: Acute renal failure in multiple myeloma. Medicine (Baltimore) 1975;54:209–223.
5.
Kyle RA: Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29–40.
6.
Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990;150:1693–1695.
7.
Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J: Renal function in newly diagnosed multiple myeloma. Eur J Haematol 1994;53:207–212.
8.
Bernstein SP, Humes HD: Reversible renal insufficiency in multiple myeloma. Arch Intern Med 1982;142:2083–2086.
9.
Cohen DJ, Sherman W, Osserman EF, Appel GB: Acute renal failure in patients with multiple myeloma. Am J Med 1984;76:247–256.
10.
Pozzi C, Pasquali S, Donini U: Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma. Clin Nephrol 1987;28:1–9.
11.
Rota S, Mougenot B, Baudouin B: Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 1987;66:126–137.
12.
Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology (BCSH): Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:410–451.
13.
International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–757.
14.
UK National Kidney Federation: Guidelines for identification, management and referral of adults with chronic kidney disease 2005. http://www.kidney.org.uk/main/guidelines/UK_CKD_guidelines-consultation-draft.pdf.
15.
Hill P, Forsyth J, Rai B, Mayne S: Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006;52:1743–1748.
16.
Paueksakon P, Revelo MP, Horn RG, Shappell S, Fogo AB: Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis 2003;42:87–95.
17.
Gavarotti P, Fortina F, Costa D, Verzetti G, Redoglia V, Boccadoro M: Benign monoclonal gammopathy presenting with severe renal failure. Scand J Haematol 1986;36:115–117.
18.
Hughes M, Davidson DF, McColl M: Outcomes of discretionary laboratory requesting of serum protein electrophoresis. Annals of Clinical Biochemistry 2006;43(Pt 5):372–374.
19.
Lindeman RD, Preuss HG: Renal physiology and pathophysiology of aging. Geriatric Nephrology and Urology 1994;4:113–120.
20.
Eisenstaedt R, Penninx BW, Woodman RC: Anemia in the elderly: current understanding and emerging concepts. Blood Reviews 2006;20:213–226.
21.
Fraser E, Macleod I, Mackinnon B, Stewart G, Simpson K, Geddes C: The aetiology of nephrotic syndrome in Scotland. NDT 2007;22(suppl 6):vi287–vi288.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.